Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma.

Král Z, Adam Z, Folber F, Moulis M, Tomíška M, Říhová L, Štork M, Buliková A, Pour L, Krejčí M, Sandecká V, Koukalová R, Řehák Z, Čermáková Z.

Vnitr Lek. 2019 Winter;65(1):37-44.

PMID:
30823836
2.

Circulating exosomal long noncoding RNA PRINS-First findings in monoclonal gammopathies.

Sedlarikova L, Bollova B, Radova L, Brozova L, Jarkovsky J, Almasi M, Penka M, Kuglík P, Sandecká V, Stork M, Pour L, Sevcikova S.

Hematol Oncol. 2018 Dec;36(5):786-791. doi: 10.1002/hon.2554. Epub 2018 Sep 13.

PMID:
30144133
3.

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients.

Stork M, Sevcikova S, Adam Z, Krejci M, Sandecka V, Kral Z, Brozova L, Velichova R, Pour L.

Neoplasma. 2018;65(4):585-591. doi: 10.4149/neo_2018_170519N363.

PMID:
29940759
4.

Liquid Biopsies - the Clinics and the Molecules.

Kubaczková V, Sedlarikova L, Bollová B, Sandecká V, Stork M, Pour L, Sevcikova S.

Klin Onkol. 2017 Summer;30(Supplementum2):13-20. doi: 10.14735/amko20172S13.

PMID:
28903565
5.

[Osteoprotective therapy with bisphosphonates or denosumab in patients with multiple myeloma: benefit and risks].

Adam Z, Straub J, Krejčí M, Pour L, Brančíková D, Ostřížková L, Sandecká V, Štork M.

Vnitr Lek. Summer 2017;63(5):311-321. Review. Czech.

PMID:
28726429
6.

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.

Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA.

Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26.

7.

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.

Sandecká V, Hájek R, Pour L, Špička I, Ščudla V, Gregora E, Radocha J, Walterová L, Kessler P, Zahradová L, Adamová D, Valentova K, Vonke I, Obernauerová J, Starostka D, Wróbel M, Brožová L, Jarkovský J, Mikulášová A, Říhová L, Ševčíková S, Straub J, Minařík J, Adam Z, Krejčí M, Král Z, Maisnar V; Czech Myeloma Group.

Eur J Haematol. 2017 Jul;99(1):80-90. doi: 10.1111/ejh.12894. Epub 2017 May 11.

PMID:
28384387
8.

[Pomalidomide in the treatment of multiple myeloma - own experience and overview of literature].

Adam Z, Pour L, Krejčí M, Vetešníková E, Sandecká V, Štork M, Čermáková Z, Pourová E, Ševčíková S, Král Z, Mayer J.

Vnitr Lek. Winter 2016;62(12):962-968. Review. Czech.

PMID:
28139124
9.

[Schnitzlers SyndromeDifferential diagnostics, an overview of therapeutic options and description of 5 cases treated with anakinra].

Adam Z, Šedivá A, Koukalová R, Řehák Z, Petrášová H, Szturz P, Adamová Z, Vetešníková E, Pour L, Krejčí M, Sandecká V, Pourová E, Čermáková Z, Ševčíková S, Král Z, Mayer J.

Vnitr Lek. Fall 2016;62(9):713-727. Review. Czech.

PMID:
27715073
10.

[Sinus histiocytosis with massive lymphadenopathy: FDG-PET/CT documented partial remission after treatment with 2-chlorodeoxyadenosine].

Adam Z, Mašlaň J, Křen L, Kodet R, Koukalová R, Řehák Z, Červinek L, Pour L, Krejčí M, Sandecká V, Král Z, Mayer J.

Vnitr Lek. Summer 2016;62(6):491-9. Czech.

PMID:
27485849
11.

[Use of new drugs within primary therapy of multiple myeloma].

Štork M, Krejčí M, Sandecká V, Král Z, Pour L.

Vnitr Lek. Spring 2016;62(5):413-22. Czech.

PMID:
27319235
12.

[Hypercalcemia, symptoms, differential diagnostics and treatment, or importance of calcium investigation].

Adam Z, Starý K, Kubinyi J, Zajíčková K, Řehák Z, Koukalová R, Tomíška M, Doubková M, Prášek J, Pourová E, Čermáková Z, Pour L, Krejčí M, Sandecká V, Ševčíková E, Ševčíková S, Král Z, Čermák A.

Vnitr Lek. Spring 2016;62(5):370-83. Czech.

PMID:
27319230
13.

[Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature].

Adam Z, Szturz P, Krejčí M, Koukalová R, Michalková E, Řehák Z, Pourová E, Pour L, Volfová P, Sandecká V, Čermáková Z, Křen L, Sokol F, Hanke I, Penka I, Petrášová H, Ševčíková S, Král Z, Mayer J.

Vnitr Lek. 2016 Apr;62(4):287-98. Review. Czech.

PMID:
27250606
14.

Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.

Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecka V, Kufova Z, Almasi M, Jarkovsky J, Gregora E, Kessler P, Wrobel M, Walker BA, Wardell CP, Morgan GJ, Hajek R, Kuglik P.

Eur J Haematol. 2016 Dec;97(6):568-575. doi: 10.1111/ejh.12774. Epub 2016 Jun 9.

PMID:
27157252
15.

Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories.

Pika T, Lochman P, Sandecka V, Maisnar V, Minarik J, Tichy M, Zapletalova J, Solcova L, Scudla V, Hajek R.

Neoplasma. 2015;62(5):827-32. doi: 10.4149/neo_2015_100.

PMID:
26278155
16.

Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.

Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, Nemec P, Mikulasova A, Almasi M, Pour L, Adam Z, Sandecka V, Zahradová L, Hajek R, Kuglik P.

Biomed Res Int. 2014;2014:209670. doi: 10.1155/2014/209670. Epub 2014 Jun 2.

17.

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.

Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R.

Haematologica. 2014 Feb;99(2):360-4. doi: 10.3324/haematol.2013.094409. Epub 2013 Sep 13.

18.

10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.

Minarik J, Sandecka V, Maisnar V, Gregora E, Spicka I, Starostka D, Plonkova H, Jarkovsky J, Walterova L, Wrobel M, Adamova D, Pika T, Melicharova H, Pour L, Radocha J, Pavlicek P, Straub J, Gumulec J, Bacovsky J, Adam Z, Scudla V, Hajek R.

Leuk Res. 2013 Sep;37(9):1063-9. doi: 10.1016/j.leukres.2013.06.019. Epub 2013 Jul 8.

PMID:
23845888
19.

[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].

Adam Z, Stork M, Pour L, Krejčí M, Zahradová L, Sandecká V, Hájek R, Cermáková Z, Pospíšilová Y, Navrátil M, Král Z, Mayer J.

Vnitr Lek. 2012 Dec;58(12):896-903. Czech.

PMID:
23427947
20.

Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.

Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. Epub 2013 Jan 4.

PMID:
23291040
21.

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

Zahradova L, Mollova K, Ocadlikova D, Kovarova L, Adam Z, Krejci M, Pour L, Krivanova A, Sandecka V, Hajek R.

Neoplasma. 2012;59(4):440-9. doi: 10.4149/neo_2012_057.

PMID:
22489700
22.

Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues.

Klincová M, Sandecká V, Mikuláiová A, Radocha J, Maisnar V, Hájek R.

Klin Onkol. 2011;24 Suppl:S14-7. Review.

PMID:
21923058
23.

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R.

Biol Blood Marrow Transplant. 2010 Apr;16(4):548-54. doi: 10.1016/j.bbmt.2009.11.025. Epub 2010 Jan 18.

24.

Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.

Krejci M, Scudla V, Tothova E, Schutzova M, Koza V, Adam Z, Krivanova A, Pour L, Buchler T, Sandecka V, Kralova D, Zahradova L, Vorlicek J, Mayer J, Hajek R.

Clin Lymphoma Myeloma. 2009 Dec;9(6):436-42. doi: 10.3816/CLM.2009.n.086.

PMID:
19951883
25.

Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.

Krejci M, Adam Z, Buchler T, Krivanova A, Pour L, Zahradova L, Holanek M, Sandecka V, Mayer J, Vorlicek J, Hajek R.

Ann Hematol. 2010 May;89(5):483-7. doi: 10.1007/s00277-009-0862-z. Epub 2009 Nov 19.

PMID:
19924414
26.

Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.

Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V, Zahradova L, Buchler T, Vorlicek J, Hajek R.

Clin Lymphoma Myeloma. 2009 Apr;9(2):151-3. doi: 10.3816/CLM.2009.n.036.

PMID:
19406726

Supplemental Content

Loading ...
Support Center